Global healthcare company GSK plc (LSE:GSK) (NYSE:GSK) announced on Friday positive headline results from an interim analysis of a phase III trial of AReSVi 006, its respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above.

RSV is a common contagious virus affecting the lungs and breathing passages.

According to an independent analysis, the vaccine candidate showed statistically significant and clinically meaningful efficacy in trial participants.

The magnitude of effect observed was consistent across RSV A and B strains, key secondary endpoints and in those aged 70 years and above.

GSK said that it plans to engage with regulators immediately and anticipates making regulatory submissions in the second half of 2022.